Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):312-20. doi: 10.1016/j.ijrobp.2010.03.011. Epub 2010 Jul 7.

Electromagnetic-guided dynamic multileaf collimator tracking enables motion management for intensity-modulated arc therapy.

Author information

1
Department of Radiation Oncology, Stanford University, Stanford, CA 94305-5847, USA. keall@stanford.edu

Abstract

PURPOSE:

Intensity-modulated arc therapy (IMAT) is attractive because of high-dose conformality and efficient delivery. However, managing intrafraction motion is challenging for IMAT. The purpose of this research was to develop and investigate electromagnetically guided dynamic multileaf collimator (DMLC) tracking as an enabling technology to treat moving targets during IMAT.

METHODS AND MATERIALS:

A real-time three-dimensional DMLC-based target tracking system was developed and integrated with a linear accelerator. The DMLC tracking software inputs a real-time electromagnetically measured target position and the IMAT plan, and dynamically creates new leaf positions directed at the moving target. Low- and high-modulation IMAT plans were created for lung and prostate cancer cases. The IMAT plans were delivered to a three-axis motion platform programmed with measured patient motion. Dosimetric measurements were acquired by placing an ion chamber array on the moving platform. Measurements were acquired with tracking, without tracking (current clinical practice), and with the phantom in a static position (reference). Analysis of dose distribution differences from the static reference used a γ-test.

RESULTS:

On average, 1.6% of dose points for the lung plans and 1.2% of points for the prostate plans failed the 3-mm/3% γ-test with tracking; without tracking, 34% and 14% (respectively) of points failed the γ-test. The delivery time was the same with and without tracking.

CONCLUSIONS:

Electromagnetic-guided DMLC target tracking with IMAT has been investigated for the first time. Dose distributions to moving targets with DMLC tracking were significantly superior to those without tracking. There was no loss of treatment efficiency with DMLC tracking.

PMID:
20615630
PMCID:
PMC2953612
DOI:
10.1016/j.ijrobp.2010.03.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center